Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Savara from “hold” to “sell,” while Weiss Ratings maintained a “sell (D-)” rating. Despite this, analysts’ overall consensus remains “Moderate Buy,” with an average price target of $10.00.
• Savara’s shares opened at $4.81, below their 50-day and 200-day moving averages, and have traded between $3.34 and $7.01 over the past year. The company reported a quarterly loss of $0.16 per share, missing estimates by $0.02.
• Institutional investors own approximately 87.93% of Savara’s stock. The clinical-stage biopharmaceutical company is developing inhaled molgramostim to treat autoimmune pulmonary alveolar proteinosis, a rare respiratory disease.

Savara (NASDAQ:SVRA - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Sunday, Wall Street Zen reports.

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Savara in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $10.00.

Savara Price Performance

SVRA stock opened at $4.81 on Friday. The company has a 50 day simple moving average of $5.38 and a 200 day simple moving average of $5.42. The stock has a market cap of $988.26 million, a price-to-earnings ratio of -8.29 and a beta of 0.20. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. Savara has a 1 year low of $3.34 and a 1 year high of $7.01.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Research analysts anticipate that Savara will post -0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Savara

Several institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. bought a new stake in Savara in the 1st quarter valued at about $57,000. Sequoia Financial Advisors LLC purchased a new position in shares of Savara in the second quarter worth about $69,000. E Fund Management Co. Ltd. purchased a new position in shares of Savara in the second quarter worth about $77,000. Inceptionr LLC bought a new stake in shares of Savara in the first quarter valued at approximately $84,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Savara in the second quarter valued at approximately $87,000. Institutional investors own 87.93% of the company's stock.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.